Adjuvant BRAF and MEK Inhibition for Melanoma: 'Impressive'

New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows 'impressive' results in relapse-free survival.
Medscape Oncology

http://ift.tt/2hseok0